Zurcher Kantonalbank Zurich Cantonalbank Sells 609 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Zurcher Kantonalbank Zurich Cantonalbank trimmed its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 18.2% in the fourth quarter, Holdings Channel reports. The firm owned 2,729 shares of the specialty pharmaceutical company’s stock after selling 609 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in ANI Pharmaceuticals were worth $150,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. increased its holdings in ANI Pharmaceuticals by 93.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 248 shares during the last quarter. Pacer Advisors Inc. acquired a new stake in ANI Pharmaceuticals in the 4th quarter valued at about $41,000. Robeco Institutional Asset Management B.V. bought a new position in ANI Pharmaceuticals during the third quarter worth about $189,000. C M Bidwell & Associates Ltd. increased its position in ANI Pharmaceuticals by 398.6% during the third quarter. C M Bidwell & Associates Ltd. now owns 3,266 shares of the specialty pharmaceutical company’s stock worth $190,000 after buying an additional 2,611 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC raised its stake in ANI Pharmaceuticals by 41.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 3,380 shares of the specialty pharmaceutical company’s stock valued at $196,000 after buying an additional 989 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

Wall Street Analyst Weigh In

ANIP has been the topic of a number of recent analyst reports. Capital One Financial assumed coverage on ANI Pharmaceuticals in a report on Friday, March 15th. They set an “overweight” rating and a $80.00 target price on the stock. Guggenheim reissued a “buy” rating and issued a $77.00 price objective on shares of ANI Pharmaceuticals in a research report on Tuesday, April 23rd. HC Wainwright lifted their target price on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the stock a “buy” rating in a report on Monday, March 4th. Finally, Truist Financial increased their price target on shares of ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a report on Friday, March 1st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $80.00.

ANI Pharmaceuticals Price Performance

Shares of ANI Pharmaceuticals stock opened at $65.62 on Thursday. The company has a 50-day simple moving average of $66.96 and a two-hundred day simple moving average of $59.36. ANI Pharmaceuticals, Inc. has a twelve month low of $38.91 and a twelve month high of $70.81. The stock has a market capitalization of $1.38 billion, a price-to-earnings ratio of 78.12 and a beta of 0.80. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Thursday, February 29th. The specialty pharmaceutical company reported $0.78 earnings per share for the quarter, beating analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $131.65 million during the quarter, compared to the consensus estimate of $123.02 million. ANI Pharmaceuticals had a net margin of 3.86% and a return on equity of 18.06%. Analysts forecast that ANI Pharmaceuticals, Inc. will post 3.55 EPS for the current year.

Insider Activity

In related news, SVP Chad Gassert sold 20,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $66.62, for a total value of $1,332,400.00. Following the transaction, the senior vice president now owns 233,226 shares in the company, valued at $15,537,516.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, SVP Chad Gassert sold 20,000 shares of the stock in a transaction that occurred on Wednesday, May 1st. The shares were sold at an average price of $66.62, for a total transaction of $1,332,400.00. Following the sale, the senior vice president now owns 233,226 shares in the company, valued at approximately $15,537,516.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Nikhil Lalwani sold 28,965 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $65.52, for a total transaction of $1,897,786.80. Following the completion of the transaction, the chief executive officer now directly owns 444,981 shares in the company, valued at $29,155,155.12. The disclosure for this sale can be found here. In the last three months, insiders sold 176,803 shares of company stock worth $11,695,866. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.